Hsp90 inhibition sensitizes DLBCL cells to cisplatin

PURPOSE: Platinum-containing therapy is standard treatment for relapsed Diffuse Large B-Cell Lymphoma (DLBCL). However, the efficacy of treatment is limited by drug resistance leading to relapse. Cisplatin resistance has been linked to impairments of the DNA damage response, and several DNA repair p...

Descripción completa

Detalles Bibliográficos
Autores principales: Schmidt, Linnéa, Issa, Issa Ismail, Haraldsdóttir, Hulda, Hald, Jonas Laugård, Schmitz, Alexander, Due, Hanne, Dybkær, Karen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956557/
https://www.ncbi.nlm.nih.gov/pubmed/35190872
http://dx.doi.org/10.1007/s00280-022-04407-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8956557/
https://www.ncbi.nlm.nih.gov/pubmed/35190872
http://dx.doi.org/10.1007/s00280-022-04407-5

Ejemplares similares